文献速递消化系统肿瘤

免疫治疗时代胃食管癌试验中无进展生存期作为总生存期替代终点的荟萃分析

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis.
PubMed 文献 · Eur J Cancer · 2025-11-29

结果显示,胃食管腺癌整体及PD-L1高表达亚组中PFS与OS治疗效应相关性中等至强,而食管鳞癌中相关性弱。PFS可作为胃食管腺癌未来免疫治疗试验的合适共同主要终点,尤其在PD-L1高表达亚组预先规划分析时。

要点

  • 胃食管腺癌整体人群PFS与OS治疗效应相关性中等(R=0.82;R2=0.52)。
  • 胃食管腺癌CPS≥5亚组相关性强(R=0.77;R2=0.85),CPS≥1亚组中等(R=0.81;R2=0.66)。
  • 食管鳞癌整体相关性弱(R=0.64;R2=0.47),CPS≥10或TPS≥1%亚组无改善。

核心结论

  • 在胃食管腺癌中,PFS对OS的替代性在PD-L1高表达亚组较好,在PD-L1低表达亚组中等,在食管鳞癌中较弱。
  • PFS可作为未来胃食管腺癌免疫检查点抑制剂试验的合适共同主要终点,尤其在PD-L1高表达亚组预先规划分析时。

研究设计与样本

  • 采用Spearman秩相关系数(R)和加权线性回归计算决定系数(R2)评估试验水平PFS对OS的替代性。

主要发现

  • 胃食管腺癌整体人群PFS与OS治疗效应相关性中等(R=0.82;R2=0.52)。
  • 胃食管腺癌CPS≥1亚组相关性中等(R=0.81;R2=0.66),CPS<1亚组中等但无统计学显著性(R=0.67;R2=0.51),CPS≥5亚组强(R=0.77;R2=0.85)。
  • 食管鳞癌整体人群相关性弱(R=0.64;R2=0.47)。
  • 食管鳞癌CPS≥10亚组(R=0.33;R2=0.16)或TPS≥1%亚组(R=0.40;R2=0.005)相关性无改善。

关键数值与推荐

  • 胃食管腺癌整体:R=0.82,R2=0.52;CPS≥1:R=0.81,R2=0.66;CPS<1:R=0.67,R2=0.51;CPS≥5:R=0.77,R2=0.85。
  • 食管鳞癌整体:R=0.64,R2=0.47;CPS≥10:R=0.33,R2=0.16;TPS≥1%:R=0.40,R2=0.005。

临床怎么用

  • 在胃食管腺癌免疫治疗试验中,可考虑将PFS作为共同主要终点,尤其在PD-L1高表达(如CPS≥5)亚组中预先规划分析。
  • 在食管鳞癌中,PFS对OS的替代性较弱,需谨慎单独使用PFS作为主要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs)-based regimens are the first-line standard of care for most patients with advanced gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC). The efficacy of these treatments often depend on PD-L1 expression levels. Overall survival (OS) has traditionally been the primary endpoint for evaluating treatment efficacy. Through a meta-analysis, we investigated whether progression-free survival (PFS) is a valid surrogate for OS in the ICIs-era, overall and across different PD-L1 subgroups. METHODS: A systematic literature review was conducted to identify eligible randomized controlled trials (RCTs) published by 30/06/2025. Trial-level surrogacy of PFS for OS was assessed using Spearman rank correlation coefficient (R) and weighted linear regression, calculating the coefficient of determination (R2). RESULTS: Eighteen eligible RCTs were evaluated. Regarding GEA, the correlation between treatment effects on PFS and on OS was moderate in the overall population (R=0.82; R2=0.52) and in the CPS≥ 1 subgroup (R=0.81; R2=0.66), moderate yet non-significant in the CPS< 1 subgroup (R=0.67; R2=0.51), and strong in the CPS≥ 5 subgroup (R=0.77; R2=0.85). In ESCC, the correlation in the overall population was weak (R=0.64; R2=0.47). No improvement of the correlation was found in the subgroup of patients with CPS≥ 10 (R=0.33; R2=0.16) or TPS≥ 1 % (R=0.40, R2=0.005). CONCLUSIONS: While the correlation between treatment effects on PFS and OS was weak in ESCC, it was moderate in PD-L1-low GEA, and good in PD-L1-high GEA. Therefore, PFS is an adequate co-primary endpoint in future trials investigating novel ICIs-based regimens in GEA, especially if the analyses are pre-planned in PD-L1-high subgroups.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Leone AG, Petrelli F, Klempner SJ, et al. Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis. Eur J Cancer. 2025. PMID: 41330053. doi:10.1016/j.ejca.2025.116155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。